Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Early Phase 1
3(75.0%)
Phase 1
1(25.0%)
4Total
Early Phase 1(3)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05700461Phase 1Enrolling By Invitation

Drug Screening Using Novel IMD in Renal Cell Carcinoma

Role: lead

NCT04135807Early Phase 1Recruiting

Implantable Microdevice In Primary Brain Tumors

Role: lead

NCT06782399Early Phase 1Not Yet Recruiting

Drug Screening of Cutaneous Lesions of Squamous Cell Carcinoma

Role: lead

NCT03972228Early Phase 1Completed

Microdevice for Evaluating Drug Response in Site in Lung Lesions

Role: lead

All 4 trials loaded